Strong Q1 Performance: Edwards Lifesciences reported first-quarter sales of $1.041 billion, reflecting an 8% year-over-year growth. This was driven by increased adoption of TAVR (Transcatheter Aortic Valve Replacement) technology and the expanding TMTT (Transcatheter Mitral and Tricuspid Therapies) portfolio.
Updated TMTT Sales Guidance: The company raised its 2025 sales guidance for TMTT to $530-$550 million due to strong momentum and favorable foreign exchange rates. This represents a significant growth of approximately 60% from the previous year, indicating successful adoption of innovative technologies like Pascal and Evoque.
TAVR Growth Outlook: Edwards maintained its full-year TAVR sales growth guidance at 5%-7% and highlighted potential expansions with upcoming indication approvals for treating asymptomatic patients. The expectation is that the approval will happen in the second quarter, which could contribute to future growth.